Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2025

Original Article

Comparison of adding SGLT2, DPP-4, or GLP-1 to insulin

Comparative outcomes of adding SGLT2 inhibitors versus incretin-based therapies to insulin in type 2 diabetes.

Diabetes research and clinical practice

Citation & Authors

Diabetes Res Clin Pract. 2025;226:112328.

Fu-Shun Yen; James Cheng-Chung Wei; Yu-Han Huang; Pei-Yun Li; Fuu-Jen Tsai; Chih-Cheng Hsu; Chii-Min Hwu

ABSTRACT · RESEARCH SUMMARY

Research summary

This Taiwanese National Health Insurance study matched 20,655 pairs of SGLT2/DPP-4 inhibitor users and 10,445 pairs of SGLT2/GLP-1 users, all receiving insulin. SGLT2 inhibitors were associated with fewer major microvascular complications, with aHRs of 0.37 and 0.57 in the two comparisons. Major cardiovascular events and death were also less frequent than with DPP-4 inhibitors.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗